早发性玻璃膜疣性黄斑病变患者中补体因子H基因罕见变异的评估
这项病例对照研究纳入89例55岁及以下诊断的早发性玻璃膜疣性黄斑病变(EODM)患者和91例65岁及以上诊断的年龄相关性黄斑变性(AMD)患者,比较基因型和表型特征。结果显示EODM患者遗传风险评分较低,但CFH基因罕见变异携带率更高(30.3% vs 7.7%),且携带罕见CFH变异与EODM相关(OR 7.2)。EODM患者中较大黄斑玻璃膜疣面积的比例也更高。
要点
- EODM患者CFH罕见变异携带率30.3%,显著高于AMD患者的7.7%。
- 携带罕见CFH变异与EODM相关,OR为7.2(95%CI 2.7-19.6)。
- EODM患者较大黄斑玻璃膜疣面积比例14.8%,高于AMD的5.5%。
核心结论
- EODM患者中很大比例携带罕见CFH变异,且多数变异聚集于影响factor H和factor H-like 1的前7个补体控制蛋白结构域。
研究设计与样本
- 对CFH、CFI、C3、C9、CFB、ABCA4、PRPH2、TIMP3和CTNNA1基因编码区测序,基于52个AMD相关变异计算遗传风险评分(GRS),并分析彩色眼底照片表型特征。
主要发现
- EODM患者平均(SD)年龄51.8(8.7)岁,女性58例(65.2%);AMD患者平均(SD)年龄77.6(6.1)岁,女性45例(49.5%)。
- EODM患者中40/89例(44.9%)在平均(SD)年龄56.4(7.3)岁时出现地图状萎缩或脉络膜新生血管。
- EODM患者GRS低于AMD患者(1.03 vs 1.60;P = .002)。
- EODM患者中27/89例(30.3%)携带CFH基因罕见变异,AMD患者中7/91例(7.7%)携带。
- 携带罕见CFH变异与EODM相关(OR 7.2;95%CI 2.7-19.6;P < .001);EODM患者较大黄斑玻璃膜疣面积(玻璃膜疣覆盖超过50%)见于24/162眼(14.8%),AMD患者见于9/164眼(5.5%)(OR 4.57;95%CI 1.5-14.1;P = .008)。
关键数值与推荐
- EODM定义为55岁及以下诊断的玻璃膜疣性黄斑病变,AMD定义为65岁及以上诊断。
- 较大黄斑玻璃膜疣面积定义为玻璃膜疣覆盖超过50%。
- 研究支持对EODM患者进行CFH基因测序并靶向补体系统。
临床怎么用
- 对早发性玻璃膜疣性黄斑病变患者可考虑CFH基因测序,以改善遗传咨询。
- 补体系统可能是EODM的靶向治疗方向。
- EODM患者可能在较早年龄进展为晚期黄斑变性,需长期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Early-onset drusen maculopathy (EODM) is a severe disease and can lead to advanced macular degeneration early in life; however, genetic and phenotypic characteristics of individuals with EODM are not well studied. OBJECTIVE: To identify genotypic and phenotypic characteristics of individuals with EODM. DESIGN, SETTING, AND PARTICIPANTS: This case-control study collected data from the European Genetic Database from September 2004 to October 2019. A total of 89 patients with EODM diagnosed at 55 years or younger and 91 patients with age-related macular degeneration (AMD) diagnosed at 65 years or older were included. EXPOSURES: Coding regions of CFH, CFI, C3, C9, CFB, ABCA4, PRPH2, TIMP3, and CTNNA1 genes were sequenced, genetic risk scores (GRS) were calculated based on 52 AMD-associated variants, and phenotypic characteristics on color fundus photographs were analyzed comparing patients with EODM and AMD. MAIN OUTCOMES AND MEASURES: GRS, frequency of rare genetic complement variants, and phenotypic characteristics. RESULTS: This case-control study included 89 patients with EODM (mean [SD] age, 51.8 [8.7] years; 58 [65.2%] were female) and 91 patients with AMD (mean [SD] age, 77.6 [6.1] years; 45 [49.5%] female). At a mean (SD) age of 56.4 (7.3) years, 40 of 89 patients with EODM (44.9%) were affected by geographic atrophy or choroidal neovascularization. A lower GRS was observed in patients with EODM compared with patients with AMD (1.03 vs 1.60; P = .002), and 27 of 89 patients with EODM (30.3%) carried rare variants in the CFH gene compared with 7 of 91 patients with AMD (7.7%). Carriership of a rare CFH variant was associated with EODM (odds ratio, 7.2; 95% CI, 2.7-19.6; P < .001). A large macular drusen area (more than 50% covered with drusen) was observed in patients with EODM (24 of 162 eyes [14.8%]) compared with patients with AMD (9 of 164 eyes [5.5%]) (odds ratio, 4.57; 95% CI, 1.5-14.1; P = .008). CONCLUSIONS AND RELEVANCE: A large proportion of patients with EODM in this study carried rare CFH variants, with most of the identified CFH variants clustered in the first 7 complement control protein domains affecting factor H and factor H-like 1. Because EODM frequently leads to advanced macular degeneration at an early age and can result in many years of vision loss, this study supports targeting the complement system and sequencing the CFH gene in patients with EODM to improve genetic counseling and future treatments for AMD.
引用
- de Breuk A, Heesterbeek TJ, Bakker B, et al. Evaluating the Occurrence of Rare Variants in the Complement Factor H Gene in Patients With Early-Onset Drusen Maculopathy. JAMA Ophthalmol. 2021. PMID: 34647987. doi:10.1001/jamaophthalmol.2021.4102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。